广东省医保支付政策对“国谈”抗癌药使用的影响分析  

Analysis on the Impact of Medical Insurance Payment Policy on Use of National Negotiated Anticancer Drugs in Guangdong

作　　者：向国春 郭亦凌 章梦君 罗晟威 吴志明[2] 陈运山 XIANG Guo-chun;GUO Yi-ling;ZHANG Meng-jun(School of Health Management,Southern Medical University,Guangzhou,510515,China;不详)

机构地区：[1]南方医科大学卫生管理学院,广州510515 [2]南方医科大学南方医院,广州510000 [3]广州市妇女儿童医疗中心,广州510620

出　　处：《中国卫生经济》2022年第8期11-14,共4页Chinese Health Economics

基　　金：2019年度广东省哲学社会科学规划项目(GD19CGL37);广州公共卫生服务体系建设研究基地资助项目(2021-2023);南方医科大学卫生管理学院资助课题;广州市市校(院)联合资助项目(202102010163);国家卫生健康委卫生发展研究中心委托项目。

摘　　要：保障国家谈判抗癌药落地是国家谈判机制能否惠及百姓的关键。通过梳理我国保障国家谈判抗癌药落地的主要措施,分析不同医保类型患者使用国家谈判抗癌药的费用结构和特征,探讨医保的供需方政策对国家谈判抗癌药使用的影响,提出完善肿瘤治疗的费用分担机制、合理提升肿瘤诊治能力、加强医保精细化管理等建议。To guarantee the implementation of national negotiated anticancer drugs is important to benefit the tumor patients,it reviews the main methods to ensure the implementation of national negotiated anticancer drugs in China,analyzes the cost structure and characteristics of patients with different types of medical insurance,and discusses the impact of medical insurance policies on the use of the anticancer drugs.It aims to put forward suggestions,which could improve tumor treatment cost-sharing mechanism,enhance the tumor diagnosis & treatment ability policy,and strengthen the refined management of medical insurance.

关 键 词：医保支付政策 国家谈判抗癌药 广东 

分 类 号：R1-9[医药卫生—公共卫生与预防医学] R19-0